Introduction to Refractory Overactive

What is/are Refractory Overactive?

Refractory Overactive - BACKGROUND Sacral neuromodulation (SNM) has been used in the treatment of refractory overactive bladder syndrome, nonobstructive urinary retention and faecal incontinence for almost 40 years now. ^[1] BackgroundSacral neuromodulation (SNM) has been used in the treatment of refractory overactive bladder syndrome, nonobstructive urinary retention and faecal incontinence for almost 40 years now. ^[2] PurposeThe efficacy and safety of a novel remotely programmed BetterStim sacral neuromodulation (SNM) system was evaluated in patients with refractory overactive bladder (OAB) in a prospective, controlled, multicenter trial. ^[3] MATERIAL AND METHODS Prospective economic evaluation concurrent with Refractory Overactive Bladder: Sacral NEuromodulation v. ^[4] To evaluate factors associated with progression to stage 2 sacral neuromodulation (SNM) for refractory overactive bladder, urinary retention, or fecal incontinence using optimal lead placement techniques with curved stylet. ^[5] We evaluated the postoperative rate of discontinuing overactive bladder medications in patients who underwent sacral neuromodulation of refractory overactive bladder. ^[6] Refractory overactive bladder (OAB) in children can be treated with second line modalities such as as biofeedback, transcutaneous electrical stimulation (TENS), and botulinum toxin. ^[7] INTRODUCTION AND OBJECTIVES: Urodynamic studies are utilized in evaluating neurogenic bladder (NGB) and refractory overactive bladder (OAB), but are invasive and can cause significant bother to the patient. ^[8] INTRODUCTION AND OBJECTIVES: Refractory overactive bladder (OAB) has detrimental effects on quality of life, and patients often exhaust non-surgical treatment options with minimal improvement in their symptoms. ^[9] INTRODUCTION AND OBJECTIVES: Sacral neuromodulation (SNM) is a standard therapy for refractory overactive bladder (OAB). ^[10] Intra-detrusor injection therapy with onabotulinumtoxinA is generally accepted as a highly effective, minimally invasive and well-tolerated day procedure for patients with refractory overactive bladder (OAB) and neurogenic detrusor overactivity (NDO). ^[11] Botulinum neurotoxin A (BoNT-A), produced from Clostridium botulinum, has been widely used to lower urinary tract dysfunctions such as detrusor sphincter dyssynergia, refractory overactive bladder, interstitial cystitis/bladder pain syndromes, benign prostatic hyperplasia, and CP/ CPPS in urology. ^[12] Sacral neuromodulation (SNM) is an effective, minimally invasive treatment for refractory overactive bladder, non-obstructive urinary retention, and fecal incontinence. ^[13] Sacral nerve stimulation (SNS) is an effective treatment for refractory overactive bladder (OAB). ^[14] In May 2018, she elected to undergo stage 1 InterStim implantation for refractory overactive bladder. ^[15] Combination therapy is a safe and effective alternative to patients with refractory overactive bladder. ^[16] Sacral neuromodulation (SNM) is a standard therapy for refractory overactive bladder (OAB). ^[17] AIM To assess the cost-effectiveness of onabotulinumtoxinA (onabotA), implantable sacral nerve stimulation devices, percutaneous tibial nerve stimulation, anticholinergic medications and mirabegron compared with best supportive care (BSC) for management of refractory overactive bladder (OAB). ^[18]

selective bladder denervation

OBJECTIVES To determine whether the presence of detrusor overactivity (DO) is associated with the 12-week and 12-month clinical outcomes of selective bladder denervation (SBD) in women with refractory overactive bladder (OAB). ^[1] Purpose: We report 6-month efficacy and safety outcomes of selective bladder denervation in women with refractory overactive bladder. ^[2] Aims: To report 1‐year results with selective bladder denervation (SBD) of the trigone in women with refractory overactive bladder (OAB). ^[3] To report the initial clinical experience with selective bladder denervation (SBD) of the trigone in women with refractory overactive bladder (OAB). ^[4]

third line therapy

15 Identifying barriers to third-line therapy: a patient-centered approach to refractory overactive bladder A. ^[1] INTRODUCTION AND OBJECTIVES: Neuromodulation is an accepted third line therapy for the treatment of refractory overactive bladder (OAB). ^[2] 15 Identifying barriers to third-line therapy: a patient-centered approach to refractory overactive bladder A. ^[3]

refractory overactive bladder

Treatment options for refractory overactive bladder (OAB) following behavioral modifications and oral OAB medications remain limited. ^[1] Conclusion: OnabotulinumtoxinA therapy is a safe and effective solution of therapy-refractory overactive bladder. ^[2] Diagnosis included non-obstructive urine retention (5), refractory overactive bladder (3), combined retention + over active bladder (OAB) (1), pelvic pain syndrome (3) and impotence in 1 patient. ^[3] INTRODUCTION AND OBJECTIVE:Third line therapies for refractory overactive bladder (OAB) undertreat patients with only 5% of patients progressing to these invasive and/or burdensome therapies (Du et. ^[4] Objective We summarized the evidence evaluating the cost-effectiveness of sacral neuromodulation (SNM) versus onabotulinumtoxinA (BONT/A) in the treatment of refractory overactive bladder (OAB) among women. ^[5] Indications for sacral neuromodulation therapy were refractory overactive bladder OAB 35 (56. ^[6] Introduction: Augmentation cystoplasty (AC) has traditionally been used in the treatment of low capacity, poorly compliant, or refractory overactive bladder (OAB). ^[7] Background To evaluate the efficacy and safety of a novel remote programming sacral neuromodulation (SNM) system (BetterStim system) in the treatment of patients with refractory overactive bladder (OAB) for 3 years. ^[8] INTRODUCTION AND OBJECTIVE:Sacral neuromodulation is an effective treatment for refractory overactive bladder. ^[9] Specialized treatment for refractory overactive bladder includes botulinum toxin injection and sacral nerve stimulation. ^[10] Sacral neuromodulation (SNM) and Botulinum toxin A (BoNT‐A) injections are well‐known third‐line treatment options in patients with refractory overactive bladder (OAB). ^[11] The primarily targeted application has been conceived for a patch to augment the bladder in various urinary diseases including, bladder carcinoma, refractory overactive bladder, interstitial cystitis, etc. ^[12] When first- and second-line treatments fail, sacral neuromodulation can be a safe and effective option for patients with refractory overactive bladder. ^[13] To investigate whether adding an anticholinergic or beta‐3 agonist can improve the therapeutic effect of intravesical onabotuliumtoxinA injection in patients with refractory overactive bladder (OAB). ^[14] BACKGROUND Sacral neuromodulation (SNM) has been used in the treatment of refractory overactive bladder syndrome, nonobstructive urinary retention and faecal incontinence for almost 40 years now. ^[15] OBJECTIVES To determine whether the presence of detrusor overactivity (DO) is associated with the 12-week and 12-month clinical outcomes of selective bladder denervation (SBD) in women with refractory overactive bladder (OAB). ^[16] Neuromodulation encompassing sacral and peripheral modalities is an established, effective, and safe higher-order treatment option approved in the USA for managing refractory overactive bladder, non-obstructive urinary retention, and fecal incontinence. ^[17] 15 Identifying barriers to third-line therapy: a patient-centered approach to refractory overactive bladder A. ^[18] BackgroundSacral neuromodulation (SNM) has been used in the treatment of refractory overactive bladder syndrome, nonobstructive urinary retention and faecal incontinence for almost 40 years now. ^[19] PurposeThe efficacy and safety of a novel remotely programmed BetterStim sacral neuromodulation (SNM) system was evaluated in patients with refractory overactive bladder (OAB) in a prospective, controlled, multicenter trial. ^[20] MATERIAL AND METHODS Prospective economic evaluation concurrent with Refractory Overactive Bladder: Sacral NEuromodulation v. ^[21] Purpose: We report 6-month efficacy and safety outcomes of selective bladder denervation in women with refractory overactive bladder. ^[22] Aims: To report 1‐year results with selective bladder denervation (SBD) of the trigone in women with refractory overactive bladder (OAB). ^[23] To evaluate factors associated with progression to stage 2 sacral neuromodulation (SNM) for refractory overactive bladder, urinary retention, or fecal incontinence using optimal lead placement techniques with curved stylet. ^[24] We evaluated the postoperative rate of discontinuing overactive bladder medications in patients who underwent sacral neuromodulation of refractory overactive bladder. ^[25] To report the initial clinical experience with selective bladder denervation (SBD) of the trigone in women with refractory overactive bladder (OAB). ^[26] Refractory overactive bladder (OAB) in children can be treated with second line modalities such as as biofeedback, transcutaneous electrical stimulation (TENS), and botulinum toxin. ^[27] INTRODUCTION AND OBJECTIVES: Urodynamic studies are utilized in evaluating neurogenic bladder (NGB) and refractory overactive bladder (OAB), but are invasive and can cause significant bother to the patient. ^[28] INTRODUCTION AND OBJECTIVES: Neuromodulation is an accepted third line therapy for the treatment of refractory overactive bladder (OAB). ^[29] INTRODUCTION AND OBJECTIVES: Refractory overactive bladder (OAB) has detrimental effects on quality of life, and patients often exhaust non-surgical treatment options with minimal improvement in their symptoms. ^[30] INTRODUCTION AND OBJECTIVES: Sacral neuromodulation (SNM) is a standard therapy for refractory overactive bladder (OAB). ^[31] Intra-detrusor injection therapy with onabotulinumtoxinA is generally accepted as a highly effective, minimally invasive and well-tolerated day procedure for patients with refractory overactive bladder (OAB) and neurogenic detrusor overactivity (NDO). ^[32] Botulinum neurotoxin A (BoNT-A), produced from Clostridium botulinum, has been widely used to lower urinary tract dysfunctions such as detrusor sphincter dyssynergia, refractory overactive bladder, interstitial cystitis/bladder pain syndromes, benign prostatic hyperplasia, and CP/ CPPS in urology. ^[33] Sacral neuromodulation (SNM) is an effective, minimally invasive treatment for refractory overactive bladder, non-obstructive urinary retention, and fecal incontinence. ^[34] Sacral nerve stimulation (SNS) is an effective treatment for refractory overactive bladder (OAB). ^[35] 15 Identifying barriers to third-line therapy: a patient-centered approach to refractory overactive bladder A. ^[36] In May 2018, she elected to undergo stage 1 InterStim implantation for refractory overactive bladder. ^[37] Combination therapy is a safe and effective alternative to patients with refractory overactive bladder. ^[38] Sacral neuromodulation (SNM) is a standard therapy for refractory overactive bladder (OAB). ^[39] AIM To assess the cost-effectiveness of onabotulinumtoxinA (onabotA), implantable sacral nerve stimulation devices, percutaneous tibial nerve stimulation, anticholinergic medications and mirabegron compared with best supportive care (BSC) for management of refractory overactive bladder (OAB). ^[40] Anticholinergics, β3 agonists and neuromodulation are alternative therapies to manage refractory overactive bladder. ^[41]